|View printer-friendly version|
BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
“The first patient enrolled in our Phase 3 Study 106 is an important step as we move closer to bringing Plinabulin to market for CIN, which is a serious health concern and causes decreases in dose, delay of chemotherapy cycles and downgrade – or even discontinue – treatment altogether, which affects chemotherapy’s anti-cancer benefit,” said Dr.
“Given its novel mechanism of action, Plinabulin holds the promise of being a groundbreaking therapy for cancer patients with its unique ability to prevent CIN and acts as an anti-cancer drug with immune-enhancing effects,” said Dr.
Neutropenia is a common side effect of chemotherapy in cancer patients, which marks the destruction of a type of white blood cell (neutrophil) that is a key component of the innate immune system. Neutrophils are a patient’s first line of defense against infections, and patients with severe neutropenia are more susceptible to bacterial, viral and fungal infections in addition to sepsis, which require hospitalization and has a high mortality risk. Around 1 million people in the US receive chemotherapy each year. With the approval of chemotherapy with checkpoint inhibitors, chemotherapy remains a cornerstone of cancer treatment, and increase 50% from now to 2040 based on a
Cautionary Note Regarding Forward-Looking Statements
Source: BeyondSpring, Inc.